$MCK

Rodgers Thomas L sold $90K of MCK

Rodgers Thomas L (EVP, Chief Strategy & BDO) sold 123 shares of MCKESSON CORP (MCK) at $735.50 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rodgers Thomas L
Published Jun 3, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 3:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

This provides a transparent datapoint on insider activity but does not, by itself, indicate new guidance, earnings, or corporate action.

02

Market read

A routine 10b5-1 insider sale disclosure; likely low incremental trading impact absent other catalysts.

03

What to watch

Traders may over-weight single Form 4 sales; the more informative signal is whether there is a pattern of consecutive discretionary sales or a change in plan behavior (not provided here).

Relevance 6/10Novelty 6/10Timing: Filed today; sale executed 2026-06-01 under 10b5-1

Background

The article is an SEC Form 4 insider transaction disclosure for McKesson, showing an EVP/Chief Strategy & BDO selling shares under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson disclosed an officer open-market sale (123 shares) under a pre-arranged 10b5-1 plan, filed via Form 4.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by unusual volume or other new company news.

Evidence & confidence

The filing provides a specific sale datapoint, yet it is explicitly tied to a pre-arranged 10b5-1 plan, which typically dampens interpretability.

Market effects

Minimal; this is company-specific insider activity with no stated operational/financial change.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • McKesson

    Subject of the Form 4 insider sale disclosure.

  • Rodgers Thomas L

    EVP, Chief Strategy & BDO who sold 123 shares on 2026-06-01.

Related articles

$MCKMed

McKesson Q1 Earnings Call Highlights

McKesson (NYSE: MCK) reported Q1 results supported by higher prescription and specialty volumes, partially offset by lower branded-drug pricing. GLP-1 distribution revenue rose to $15B, up about $3B (24%). Full-year guidance calls for North American Pharmaceutical revenue growth of 4% to 8%. Oncology & Multispecialty profit rose 41% to $405M. McKesson repurchased $2.5B shares and expects FY27 FCF $4.5B to $4.9B.

$MCKMedAI 8/10

Highlights of McKesson’s (MCK) Q1 2027 earnings report

McKesson (MCK) reported Q1 fiscal 2027 results. Adjusted earnings rose to $9.93 per share from $8.26 a year earlier, beating analysts. Unadjusted net income was $614 million, or $5.17 per share. Revenue increased to $105.4 billion from $97.83 billion. The company raised FY27 adjusted EPS guidance to $44.20 to $45.00.

$MCKHighAI 9/10

[MCK Q1 2027 Earnings Call] McKesson Lifts Full-Year EPS Target as North American Pharma Profit Soars 19% — BigGo Finance

McKesson reported fiscal Q1 2027 revenue of $105.4B, up 8%, and adjusted EPS of $9.93, up 20%, citing stronger North American Pharmaceutical margins. North American Pharma operating profit rose 19% to $894M on 5% revenue growth, with GLP-1 distribution revenue at $15B (+24%). McKesson raised full-year adjusted EPS guidance to $44.20–$45.00 and returned $2.6B to shareholders.